Could the Endocannabinoid System Explain Why Different Depression Treatments All Work?
Multiple treatments for treatment-resistant depression, from brain stimulation to ketamine to psychedelics, may all work in part by modulating the endocannabinoid system, positioning it as a unifying therapeutic target.
Quick Facts
What This Study Found
This review synthesizes evidence that diverse non-monoaminergic treatments for treatment-resistant depression all influence the endocannabinoid system. Brain stimulation (rTMS, ECT) elevates anandamide and 2-AG levels, correlating with clinical improvement. Ketamine and esketamine modulate CB1 receptors. Psilocybin restores 2-AG and enhances CB1 expression in mood-related brain regions, while LSD affects the broader endocannabinoidome in the prefrontal cortex and hippocampus.
Key Numbers
Approximately one-third of depression patients are treatment-resistant. The review covers rTMS, ECT, ketamine, esketamine, psilocybin, and LSD, all showing ECS modulation.
How They Did This
Narrative review drawing from preclinical and clinical literature on the endocannabinoid system's role in depression and its involvement in non-monoaminergic treatments effective for treatment-resistant depression.
Why This Research Matters
Treatment-resistant depression affects roughly a third of people with depression. Understanding why very different treatments (electrical stimulation, ketamine, psychedelics) can all be effective could lead to better-targeted therapies. The endocannabinoid system may be the common thread connecting these diverse approaches.
The Bigger Picture
If the endocannabinoid system truly serves as a shared pathway for multiple antidepressant treatments, it could shift how treatment-resistant depression is understood and treated. Rather than trying different medications hoping one works, clinicians might eventually target ECS function directly.
What This Study Doesn't Tell Us
Narrative review, not systematic. Much of the ECS evidence comes from preclinical models. The causal direction is not established. Limited human data on ECS biomarkers during treatment.
Questions This Raises
- ?Could direct ECS-targeting drugs treat depression more effectively than current options?
- ?Do individual differences in ECS function predict which treatment-resistant patients respond to which treatments?
- ?Would combining ECS-targeted approaches with existing treatments improve outcomes?
Trust & Context
- Key Stat:
- Multiple TRD treatments all modulate the endocannabinoid system
- Evidence Grade:
- Moderate: synthesizes substantial preclinical and some clinical evidence, but narrative rather than systematic approach.
- Study Age:
- Published in 2025.
- Original Title:
- Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.
- Published In:
- Psychiatry research, 352, 116697 (2025)
- Authors:
- Rosa, Ilenia, Padula, Lorenzo Pio, Semeraro, Francesco, Marrangone, Carlotta, Inserra, Antonio, De Risio, Luisa, Boffa, Marta, Zoratto, Francesca, Borgi, Marta, Guidotti, Roberto, Lorenzo, Giorgio Di, D'Addario, Claudio, Pettorruso, Mauro, Martinotti, Giovanni
- Database ID:
- RTHC-07520
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Is the endocannabinoid system involved in depression?
Growing evidence suggests the endocannabinoid system is a critical mood regulator. Multiple effective depression treatments, including brain stimulation and ketamine, appear to work partly by modulating this system.
Could cannabis-based treatments help with treatment-resistant depression?
While the endocannabinoid system appears important in depression, this review focuses on how other treatments (not cannabis itself) modulate this system. Direct cannabinoid therapies for depression remain an active area of research.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-07520APA
Rosa, Ilenia; Padula, Lorenzo Pio; Semeraro, Francesco; Marrangone, Carlotta; Inserra, Antonio; De Risio, Luisa; Boffa, Marta; Zoratto, Francesca; Borgi, Marta; Guidotti, Roberto; Lorenzo, Giorgio Di; D'Addario, Claudio; Pettorruso, Mauro; Martinotti, Giovanni. (2025). Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.. Psychiatry research, 352, 116697. https://doi.org/10.1016/j.psychres.2025.116697
MLA
Rosa, Ilenia, et al. "Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.." Psychiatry research, 2025. https://doi.org/10.1016/j.psychres.2025.116697
RethinkTHC
RethinkTHC Research Database. "Endocannabinoids, depression, and treatment resistance: Pers..." RTHC-07520. Retrieved from https://rethinkthc.com/research/rosa-2025-endocannabinoids-depression-and-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.